Registration has ended
Info
ISPE Emerging Leaders - ATMP Online Seminar Series - Vol III.
Tissue engineered products
The ISPE Emerging Leaders invite you to join our online seminar series 2022. In multiple volumes, you will learn about ATMP related topics. We will cover the basics of cell and gene therapy and tissue engineering, new manufacturing processes and the implications of these novel products on engineering and regulatory aspects.
This event is a joint initiative of the ISPE Emerging Leaders groups of the D/A/CH and Belgium affiliate.
For more information on the upcoming sessions, subscribe to our newsletter by checking the box in the registration form or follow us on LinkedIn.
Program - Vol III. - 30.11.2022
Time | Presenter | Topic |
17:30 - 17:40 | ISPE Emerging Leaders | Welcome by the moderators and introduction to ISPE Emerging Leaders and the seminar series |
17:40 - 18:10 | Bert van den Bogerd | Designer descemet membranes for corneal tissue engineering to solve a global donor shortage |
18:10 - 18:40 | Andreas Eberle | An overview lecture on the industrial production of ATMP in the field of tissue engineering |
18:40 - 19:30 | All | Open Q&A with possibility to network with other participants |
More information about the speakers:
Andreas Eberle
VP Plant Manager - CO.DON AG
Dr. Andreas Eberle serves as VP Plant Manager Leipzig, bringing with him broad experience in the pharmaceutical industry with regard to planning and implementation of pharmaceutical facilities, aseptic processing and leadership of commercial pharmaceutical facilities around the whole supply chain.
With over 25 years of experience in the pharmaceutical industry, such as qualification, validation, engineering, process development, process optimization, and management of large production units, he ensures that Manufacturing department is the heart of CO.DON.
Andreas previously (from 2012 to 2017) served as Senior Director of IDT Biologika GmbH and headed the drug product department including compounding, aseptic filling and visual inspection. He successfully implemented a new visual inspection strategy, realigned and restructured the pharmaceutical production department.
From 2008 to 2012 Andreas was Director Production at ratiopharm (Merckle GmbH), leading a biopharmaceutical production unit including compounding, aseptic pre-filled syringe filling, visual inspection and packaging. At the same time, he worked on a project to license a new product on the market and implemented it at a CMO (contract manufacturing organization).
Prior to that, he served as Associate Director of a biopharmaceutical development department at Johnson & Johnson. There he focused on planning, development, implementation and validation of products within pre-filled syringes. He also successfully realized and worked in projects to develop an autoinjector and a safety syringe device. In this responsibility he worked within a project to invent a stacked needle part and this could be successfully patent by J & J.
From 1999 to 2005 Andreas joined Aventis Behring and worked as Senior Manager within the Qualification department and production department. During this time he also headed a qualification project in Vienna, Austria.
Andreas started his career as a consultant engineer for Qualification/Validation at LSMW GmbH.
Bert van den Bogerd
Post-Doctoral Researcher - University of Antwerp, Antwerp Research Group for Ocular Science
Bert Van den Bogerd (°1992) received his master degree in Molecular and Cellular Biomedical Sciences magna cum laude in 2015 at the University of Antwerp. He obtained his PhD degree at the same university, supported by an FWO SB mandate, and the topic of his PhD was “The development of corneal endothelial substrates to regenerate the human cornea”. Bert has spent several months abroad to train the latest experimental techniques at renowned tissue engineering laboratories under the guidance of Prof. dr. Stefano Ferrari (Venice, Italy), Prof. dr. Goran Petrovski (Szeged, Hungary) and Prof. dr. Barbara Zavan (Padua, Italy) for which he received travel grants from the EU through the COST action networks. Additionally, he enlisted several summer schools and trainings throughout Europe at Uniklinik Köln (Germany), Varna Medical University (Bulgaria), Zagreb University (Croatia), C-COMEND course Barcelona (Spain) and Malta University (Malta).
During his PhD, Bert was awarded three research grants from the Funds for Research in Ophthalmology (2015, 2016 and 2017) for over 25,000€ to support his research involved in corneal cell therapies. In 2016 he was awarded with the Best Student prize during the summer school at the Varna Medical University and in 2018, he received the Best Student Award (1,000€ travel grant) at the interdisciplinary educational Master programme at the Université Libre de Bruxelles, which was awarded by Nobel prize winner Dr. Jean Tirole, supported by the Funds Baillet-Latour. In 2020, Dr. Van den Bogerd won the Flemish PhD Cup, both the jury’s prize and the popular vote. Recently, he was also award with the RegMedNet rising star award which is an initiative aiming to recognize early-career scientists for their incredible work revolutionizing in the field of regenerative medicine.
Currently, he is postdoctoral researcher and team leader of the Antwerp Research Group for Ocular Science (ARGOS). His research is focused on corneal cell (based) therapy with the special emphasis on targeted drug delivery, organ-on-chip technology and photopolymerizable biomaterials. He published 15 international peer-reviewed papers and a patent to treat eye disorders. Of note, he published a peer-reviewed letter to the editor as first author in The New England Journal of Medicine, the world’s most renowned scientific journal. At this moment, Bert is supervising two PhD students as promotor and has supervised several >10 Master and Bachelor students in his laboratory. Based on his gathered expertise in the field of cell (based) therapy, dr. Van den Bogerd is an appointed expert for the forthcoming consultation of the 5th Edition Guide on quality and safety of tissues and cells of human application of the European Directorate for the quality of medicines and Healthcare (Council of Europe).
------